Skip to main content

Compare Stocks

Date Range: 

 Bioanalytical SystemsAuxly Cannabis GroupPieris PharmaceuticalsLuna InnovationsEloxx Pharmaceuticals
SymbolNASDAQ:BASIOTCMKTS:CBWTFNASDAQ:PIRSNASDAQ:LUNANASDAQ:ELOX
Price Information
Current Price$23.14$0.27$1.88$11.67$1.35
52 Week RangeBuyBuyBuyBuyHold
MarketRank™
Overall Score1.21.41.41.31.2
Analysis Score1.53.53.52.53.0
Community Score2.33.02.62.52.5
Dividend Score0.00.00.00.00.0
Ownership Score1.70.00.80.80.0
Earnings & Valuation Score0.60.60.00.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$17.00$0.40$9.00$14.50$4.00
% Upside from Price Target-26.53% downside47.33% upside378.72% upside24.25% upside196.30% upside
Trade Information
Market Cap$257.57 million$203.55 million$119.01 million$366.42 million$64.61 million
Beta1.920.611.41.232.57
Average Volume122,9251,943,103540,237204,361219,525
Sales & Book Value
Annual Revenue$60.47 million$6.29 million$46.28 million$70.52 millionN/A
Price / Sales4.2632.362.575.20N/A
Cashflow$0.04 per shareN/AN/A$0.32 per shareN/A
Price / Cash558.40N/AN/A36.78N/A
Book Value$0.69 per share$0.31 per share$0.93 per share$2.40 per share$0.91 per share
Price / Book33.540.882.024.86N/A
Profitability
Net Income$-4,680,000.00$-77,300,000.00$-25,470,000.00$5.34 million$-50,870,000.00
EPS($0.35)N/A($0.56)$0.17($1.34)
Trailing P/E RatioN/AN/AN/A64.83N/A
Forward P/E Ratio578.50N/A44.88N/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-7.75%-332.96%-59.11%7.21%N/A
Return on Equity (ROE)-42.74%-47.37%-55.20%10.72%-163.87%
Return on Assets (ROA)-6.38%-28.34%-21.21%8.32%-89.65%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio2.49%0.53%N/AN/A0.52%
Current Ratio0.48%1.82%4.50%4.37%3.23%
Quick Ratio0.46%0.91%4.50%3.57%3.23%
Ownership Information
Institutional Ownership Percentage10.62%0.01%57.46%42.38%21.49%
Insider Ownership Percentage11.46%N/A6.59%11.20%33.40%
Miscellaneous
Employees39743111141125
Shares Outstanding11.13 million749.71 million63.30 million31.40 million47.86 million
Next Earnings DateN/A6/7/2021 (Estimated)5/17/2021 (Estimated)5/17/2021 (Confirmed)8/5/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableNot OptionableOptionable
SourceHeadline
Eloxx Pharmaceuticals Prices Public Offering of 33.3M Shares at $1.35 EachEloxx Pharmaceuticals Prices Public Offering of 33.3M Shares at $1.35 Each
marketwatch.com - May 14 at 12:26 PM
Why Bionano Genomics, CorMedix and Eloxx Are Moving FridayWhy Bionano Genomics, CorMedix and Eloxx Are Moving Friday
markets.businessinsider.com - May 14 at 11:12 AM
Eloxx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common StockEloxx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - May 14 at 7:26 AM
Eloxx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common StockEloxx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
finance.yahoo.com - May 14 at 12:47 AM
Eloxx Pharmaceuticals (NASDAQ:ELOX) Issues Quarterly  Earnings Results, Misses Expectations By $0.06 EPSEloxx Pharmaceuticals (NASDAQ:ELOX) Issues Quarterly Earnings Results, Misses Expectations By $0.06 EPS
americanbankingnews.com - May 10 at 7:38 AM
Eloxx Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides ...Eloxx Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides ...
apnews.com - May 6 at 6:23 PM
Eloxx Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides Business UpdateEloxx Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides Business Update
finance.yahoo.com - May 6 at 6:23 PM
Zacks: Analysts Expect Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Will Post Earnings of -$0.16 Per ShareZacks: Analysts Expect Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Will Post Earnings of -$0.16 Per Share
americanbankingnews.com - May 5 at 7:14 PM
BRIEF-Eloxx Pharmaceuticals Adds Additional Treatment Arm To Ongoing Phase 2 Clinical Studies For Cystic FibrosisBRIEF-Eloxx Pharmaceuticals Adds Additional Treatment Arm To Ongoing Phase 2 Clinical Studies For Cystic Fibrosis
msn.com - April 29 at 8:30 PM
Eloxx Pharmaceuticals Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies for Cystic FibrosisEloxx Pharmaceuticals Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis
finance.yahoo.com - April 29 at 5:39 PM
Eloxx Pharmaceuticals (ELOX) Is in Oversold Territory: Whats Next?Eloxx Pharmaceuticals (ELOX) Is in Oversold Territory: What's Next?
finance.yahoo.com - April 20 at 10:01 AM
Eloxx Buys Zikani Therapeutics In An All-Stock Deal; Shares GainEloxx Buys Zikani Therapeutics In An All-Stock Deal; Shares Gain
finance.yahoo.com - April 5 at 12:45 PM
Eloxx nabs early-stage biotech Zikani Therapeutics, replaces CEO, research leadEloxx nabs early-stage biotech Zikani Therapeutics, replaces CEO, research lead
fiercebiotech.com - April 1 at 12:17 PM
Eloxx Stock is Trading Higher After Zikani Therapeutics AcquisitionEloxx Stock is Trading Higher After Zikani Therapeutics Acquisition
finance.yahoo.com - April 1 at 12:17 PM
Eloxx Pharma Acquires Zikani TherapeuticsEloxx Pharma Acquires Zikani Therapeutics
markets.businessinsider.com - April 1 at 8:44 AM
BRIEF-Eloxx Pharmaceuticals Acquires Zikani TherapeuticsBRIEF-Eloxx Pharmaceuticals Acquires Zikani Therapeutics
msn.com - April 1 at 8:44 AM
Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operating Results ...Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operating Results ...
apnews.com - March 12 at 1:43 AM
Eloxx Pharmaceuticals, Inc. (ELOX) Q4 2020 Earnings Call TranscriptEloxx Pharmaceuticals, Inc. (ELOX) Q4 2020 Earnings Call Transcript
finance.yahoo.com - March 12 at 1:28 AM
Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operating Results and Provides Business UpdateEloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operating Results and Provides Business Update
finance.yahoo.com - March 11 at 6:08 PM
Eloxx Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide ...Eloxx Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide ...
apnews.com - March 5 at 1:00 AM
Eloxx Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on March 11, 2021Eloxx Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on March 11, 2021
finance.yahoo.com - March 4 at 7:59 PM
Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)’s 23.22% Gain This Week Just Tells Us Something NewEloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)’s 23.22% Gain This Week Just Tells Us Something New
marketingsentinel.com - March 1 at 12:21 PM
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Cystic FibrosisEloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Cystic Fibrosis
finance.yahoo.com - February 9 at 7:23 AM
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical Pharmacology in Drug DevelopmentEloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical Pharmacology in Drug Development
finance.yahoo.com - January 26 at 7:31 AM
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical ...Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical ...
apnews.com - January 21 at 2:09 AM
DateCompanyBrokerageAction
3/9/2021Bioanalytical SystemsColliers SecuritiesReiterated Rating
3/10/2021Auxly Cannabis GroupCantor FitzgeraldInitiated Coverage
9/1/2020Auxly Cannabis GroupRaymond JamesReiterated Rating
7/16/2020Auxly Cannabis GroupDesjardinsInitiated Coverage
4/26/2021Pieris PharmaceuticalsHC WainwrightReiterated Rating
8/9/2020Pieris PharmaceuticalsWilliam BlairReiterated Rating
3/13/2020Pieris PharmaceuticalsRobert W. BairdUpgrade
5/13/2019Pieris PharmaceuticalsCowenReiterated Rating
3/12/2021Luna InnovationsB. RileyBoost Price Target
3/6/2020Luna InnovationsNorthland SecuritiesDowngrade
10/2/2018Luna InnovationsDawson JamesInitiated Coverage
6/10/2020Eloxx PharmaceuticalsCitigroupDowngrade
5/12/2020Eloxx PharmaceuticalsCanaccord GenuityReiterated Rating
5/8/2020Eloxx PharmaceuticalsJanney Montgomery ScottLower Price Target
5/8/2020Eloxx PharmaceuticalsPiper SandlerLower Price Target
8/8/2019Eloxx PharmaceuticalsSunTrust BanksLower Price Target
(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.